Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Expanding on an earlier pact, AbbVie will pay Harpoon Therapeutics $50 million for an option to license HPN217, a bispecific antibody that targets B-cell maturation antigen, and to add six targets to the firms’ existing discovery deal. Harpoon could get another $50 million when the first person is treated with HPN217 in the clinic. AbbVie will decide whether to buy global rights to the drug after a planned Phase I/II study in multiple myeloma is completed.
This article has been sent to the following recipient: